Tagged with BI

Pharma The general manager of Drogsan, Ersan Kuçuk elaborates on the company’s efforts in shifting towards more value-added pharmaceutical products, specifically within the realm of biosimilars, while highlighting his ambitions in expanding the company’s presence within OTC. He also illustrates the decision to move Drogsan’s R&D department to the Gazi University…

Pharma Over the past few years BMS has consolidated its footprint in Puerto Rico to transform the island into a manufacturing hub for both biopharma and pharmaceuticals. The plant manager of the oral solid Humacao plant discusses the current challenges the site is facing as well as the company’s future development…

Pharma Puerto Rico is not only an important manufacturing hub, but is also positioning itself as a state-of-the-art center for R&D and clinical research. Iván Lugo, the executive director of the Industry University Research Center Inc. (INDUNIV), which brings together private sector, academia and government, discusses some of the island’s most…

Pharma Maribel Rodríguez-Torres of Fundación de Investigación assesses the current R&D situation in Puerto Rico, explains the activities of the center as well as some of their most important success stories. The Fundación is Puerto Rico’s largest research center and the only Phase 1 research clinical trials unit in Latin America and the Caribbean. What is your assessment…

pharma Ileana Quiñones, president and general manager of iPR-AstraZeneca, discusses the clear strategy of the affiliate in being a leading manufacturer in Puerto Rico and the steps necessary to ensure their place in the country and within the AstraZeneca organization. Where is AstraZeneca focused today and how does the Puerto Rican…

pharma Haluk Ataoglu, academic turned founder of Matriks Biotek®, talks about his aspirations for his company and the Turkish R&D landscape as well as how to penetrate the global pharmaceutical market as a Turkish brand. As an introduction Haluk, can you tell us what your initial aspirations were in starting Matriks…

pharma Prof. Dr. Murat Özgören, the architect behind the ambitious BioIzmir project, talks about its potential and how it intends to educate new talent to address critical future needs of the pharmaceutical industry. To begin, Dr. Özgören, could you give us an overview of the intent behind the BioIzmir project? The…

Pharma The Chairman & CEO of DBV Technologies reveals how they have developed a new therapeutic method and new technology in the form of a patch to treat various allergies. DBV received a “breakthrough” designation from the FDA for the design which meets safety standards that no other products currently being developed do.…

Pharma Frank Grosveld, Professor of Molecular Biology at Erasmus Medical Center, tells PharmaBoardroom about how Dutch research and development environment has evolved over recent decades.  Frank, to begin could you please introduce yourself to our readers around the world, with reference to your current research interests and educational responsibilities? I am…

Pharma Miroslav Secerov, VP Sales & Marketing NATEC, explains the choice of Mauritius for NATEC’s headquarters as well as the unique assets that make Mauritius the ideal business location. He also analyses Mauritius’ recent emphasis on development of the life sciences sector and the public-private relationship required to make that a…

Pharma The General Manager of LEEM talks about the association’s strategy based on three key points, innovation, attractiveness and efficiency; how the Mediator affair has placed a question mark on the championing of the pharma industry as a national asset; why both France and Europe are at turning point and what…

Pharma Colette Alma-Zeestraten tells PharmaBoardroom about how the Dutch Pharma Industry is adapting, how it is making use of clusters to become more competitive, energy efficient, and innovative, and how the nine billion euro contribution the pharmaceuticals sector makes to the Dutch chemicals industry. Over your last 10 years at the VNCI, what…